GenEdit

Designing nanoparticles that can get genetic medicines to their targets

First Investment: 2018

Gene-based medicines, in the form of DNA, RNA, and ribonuclear proteins, promise to help treat many diseases caused by genetic mutations. But one huge challenge of genetic medicine has been figuring out how to deliver these fragile molecules to the right places in the body. Genedit designs polymer nanoparticles of varied size, charge, and composition that can selectively deliver genetic payloads to specific tissues such as in the lungs or the central nervous system.

News & Insights

News

DCVC Bio leads GenEdit’s $8.5 Million Seed Round: Safe, efficient CRISPR and gene therapy delivery platform proven across multiple diseases and cell types

By Matthew Ocko, Zachary Bogue

Explore Companies

Radionetics Oncology

Discovering more precise ways to deploy radiopharmaceuticals against solid tumors

DVLP Medicines

Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing

Noetik

Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer

Solu Therapeutics

Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules